Evidence map›Paper›PMID 38712115›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Age and gender profiles of HIV infection burden and viraemia: novel metrics for HIV epidemic control in African populations with high antiretroviral therapy coverage.

Andrea Brizzi, Joseph Kagaayi, Robert Ssekubugu, Lucie Abeler-Dörner, Alexandra Blenkinsop, David Bonsall, Larry W Chang, Christophe Fraser, Ronald M Galiwango, Godfrey Kigozi and 11 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Andrea BrizziDepartment of Mathematics, Imperial College London, London, United Kingdom.ORCID 0000-0002-5639-8260
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.ORCID 0000-0003-4101-3038
Robert SsekubuguRakai Health Sciences Program, Kalisizo, Uganda.
Lucie Abeler-DörnerBig Data Institute, University of Oxford, Oxford, United Kingdom.
Alexandra BlenkinsopDepartment of Mathematics, Imperial College London, London, United Kingdom.
David BonsallBig Data Institute, University of Oxford, Oxford, United Kingdom.
Larry W ChangDivision of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Christophe FraserBig Data Institute, University of Oxford, Oxford, United Kingdom.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Godfrey KigoziRakai Health Sciences Program, Kalisizo, Uganda.
Imogen KyleDepartment of Mathematics, Imperial College London, London, United Kingdom.
Mélodie MonodDepartment of Mathematics, Imperial College London, London, United Kingdom.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Fred NalugodaRakai Health Sciences Program, Kalisizo, Uganda.
Joseph G RosenDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-4991-4033
Oliver LaeyendeckerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6429-4760
Thomas C QuinnDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
M Kate GrabowskiRakai Health Sciences Program, Kalisizo, Uganda.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.
Oliver RatmannDepartment of Mathematics, Imperial College London, London, United Kingdom.ORCID 0000-0001-8667-4118
Rakai Health Sciences Program

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
Neurologic Sequelae of HIV Subtype A and D Infection and ART Rakai UgandaR01MH099733 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SACKTOR, NED C, WAWER, MARIA J · 2013 to 2017
$3.0M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
Genital Anaerobes, Inflammation and HIV Risk; RakaiR01AI087409 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H, PRICE, LANCE BRADLEY · 2010 to 2012
$2.5M
Alcohol Epidemiology and Pilot Intervention to Reduce Alcohol, IPV and HIV in Women in UgandaK01AA024068 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WAGMAN, JENNIFER ANN · 2015 to 2019
$917k
Assessing the impact of an intervention to prevent violence and HIV in UgandaF31MH095649 · NIMH · JOHNS HOPKINS UNIVERSITY · PI WAGMAN, JENNIFER ANN · 2011 to 2013
$84k
Intramural NIH HHS ZIA AI001040NIAAA NIH HHS K01 AA024068NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI087409NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NIMH NIH HHS F31 MH095649NIMH NIH HHS R01 MH099733NIMH NIH HHS R01 MH107275
6 · The paper itself

Abstract

Introduction: To prioritize and tailor interventions for ending AIDS by 2030 in Africa, it is important to characterize the population groups in which HIV viraemia is concentrating. Methods: We analysed HIV testing and viral load data collected between 2013-2019 from the open, population-based Rakai Community Cohort Study (RCCS) in Uganda, to estimate HIV seroprevalence and population viral suppression over time by gender, one-year age bands and residence in inland and fishing communities. All estimates were standardized to the underlying source population using census data. We then assessed 95-95-95 targets in their ability to identify the populations in which viraemia concentrates. Results: Following the implementation of Universal Test and Treat, the proportion of individuals with viraemia decreased from 4.9% (4.6%-5.3%) in 2013 to 1.9% (1.7%-2.2%) in 2019 in inland communities and from 19.1% (18.0%-20.4%) in 2013 to 4.7% (4.0%-5.5%) in 2019 in fishing communities. Viraemia did not concentrate in the age and gender groups furthest from achieving 95-95-95 targets. Instead, in both inland and fishing communities, women aged 25-29 and men aged 30-34 were the 5-year age groups that contributed most to population-level viraemia in 2019, despite these groups being close to or had already achieved 95-95-95 targets. Conclusions: The 95-95-95 targets provide a useful benchmark for monitoring progress towards HIV epidemic control, but do not contextualize underlying population structures and so may direct interventions towards groups that represent a marginal fraction of the population with viraemia.

Indexed as

population-based studyprospective cohortsub-Saharan AfricaUniversal Test and Treatviraemiaviral load suppression

Identifiers

PMID38712115
PMCPMC11071606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.